類澱粉沉積症藥物市場規模、佔有率、成長分析（按治療類型、給藥途徑、應用、最終用戶、分銷管道和地區）- 2025 年至 2032 年行業預測

預計 2023 年全球類澱粉沉積症藥物市場價值將達到 201 億美元，從 2024 年的 228.5 億美元成長到 2032 年的 638.3 億美元，預測期內（2025-2032 年）的複合年成長率為 13.7%。

全球類澱粉沉積症治療市場正經歷強勁成長，這得益於類澱粉沉積症盛行率的提高和認知度的提高，以及臨床實踐和診斷技術的重大進步。創新的標靶治療正在獲得認可，從而推動了對安寧療護解決方案的需求。人口老化，尤其是越來越多的具有遺傳傾向的人群，正在促進市場擴張，而有利的政府政策和孤兒藥激勵措施正在推動治療藥物的採用。醫療保健專業人員和患者意識的提高有助於早期發現症狀。此外，人工智慧、機器學習、物聯網和擴增實境等技術的融合正在徹底改變藥物發現、精準醫療、病患監測和診斷影像，最終改善類澱粉沉積症治療的治療效果和法規遵循。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管格局
• 客戶和購買標準分析
• 管道分析
• 疾病流行病學

類澱粉沉積症藥物市場規模（依治療類型及複合年成長率）（2025-2032）

• 市場概況
• 化療
• 幹細胞移植
• 標靶治療
• 支持性治療和手術
• 其他

類澱粉沉積症藥物市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概況
• 口服
• 靜脈
• 皮下

類澱粉沉積症藥物市場規模（按應用和複合年成長率）（2025-2032）

• 市場概況
• AL類澱粉沉積症
• ATTR類澱粉沉積症
• AA類澱粉沉積症
• 野生型 ATTR

類澱粉沉積症藥物市場規模（依最終用戶和複合年成長率）(2025-2032)

• 市場概況
• 醫院和診所
• 門診手術中心
• 居家照護環境
• 其他

類澱粉沉積症藥物市場規模（按分銷管道和複合年成長率）（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥局
• 線上

類澱粉沉積症藥物市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比比較（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• Alnylam Pharmaceuticals（USA）
• Ionis Pharmaceuticals（USA）
• AstraZeneca（UK）
• Johnson & Johnson（USA）
• Novo Nordisk A/S（Denmark）
• BridgeBio Pharma（USA）
• Prothena Corporation（Ireland）
• Alexion Pharmaceuticals（USA）
• Takeda Pharmaceutical Company（Japan）
• Attralus（USA）
• Caelum Biosciences（USA）
• Zentalis Pharmaceuticals（USA）
• GlaxoSmithKline plc（GSK）（UK）
• Intellia Therapeutics（USA）
• Sanofi（France）
• F. Hoffmann-La Roche（Switzerland）
• Akcea Therapeutics（USA）
• Bristol-Myers Squibb Company（USA）
• Regeneron Pharmaceuticals（USA）

結論和建議

Global Amyloidosis Therapeutics Market size was valued at USD 20.1 billion in 2023 and is poised to grow from USD 22.85 billion in 2024 to USD 63.83 billion by 2032, growing at a CAGR of 13.7% during the forecast period (2025-2032).

The global amyloidosis therapeutics market is experiencing robust growth driven by the increasing prevalence and awareness of amyloidosis, along with significant advancements in clinical practices and diagnostic technologies. The rising acceptance of innovative and targeted therapies enhances the market landscape, generating demand for palliative care solutions. The aging population, particularly those with genetic predispositions, contributes to market expansion, supported by favorable government policies and orphan drug incentives that encourage the adoption of therapeutics. Enhanced awareness among healthcare professionals and patients facilitates the early identification of symptoms. Additionally, the integration of technologies such as AI, machine learning, IoT, and AR is revolutionizing drug discovery, precision medicine, patient monitoring, and diagnostic imaging, ultimately improving treatment outcomes and regulatory compliance in amyloidosis care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Therapeutics Market Segments Analysis

Global Amyloidosis Therapeutics Market is segmented by Therapy Type, Route of Administration, Application, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Stem Cell Transplantation, Targeted Therapy, Supportive Care & Surgery and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Application, the market is segmented into AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis and Wild-Type ATTR. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is significantly driven by the growing incidence of amyloidosis, attributed to heightened awareness and improved diagnostic techniques. This surge in understanding fosters a robust demand for therapeutics specifically targeting the condition. Additionally, the increasing adoption of innovative treatment options and advanced diagnostic methods is propelling market expansion, especially since amyloidosis is a rare disease that frequently remains undetected. Furthermore, enhanced healthcare reimbursement policies play a vital role in promoting both the diagnosis and treatment of amyloidosis, thereby further stimulating the market's growth and accessibility for affected patients.

Restraints in the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market faces several challenges that hinder patient adoption and pharmaceutical investment. The substantial expenses associated with advanced medications, specialized treatments, and ongoing care create financial barriers for individuals seeking amyloidosis therapeutics. Additionally, the high costs involved in researching and developing innovative drugs, including RNA-based therapies, deter pharmaceutical companies from pursuing further exploration in this field. Furthermore, the rare and severe nature of amyloidosis, combined with its potential for fatal outcomes, leads many patients to be reluctant in embracing these therapies. Consequently, these factors collectively contribute to a constrained market environment for amyloidosis treatments.

Market Trends of the Global Amyloidosis Therapeutics Market

The Global Amyloidosis Therapeutics market is witnessing a significant trend towards the adoption of RNA-based therapies, driven by their heightened efficacy and cost-effectiveness. Patients increasingly favor these therapies as they address the root causes of the disease, providing long-term solutions with fewer doses required. Furthermore, the surge in research and development efforts coupled with innovative advancements from biotech firms and pharmaceutical companies is bolstering patient confidence in RNA-based treatments. This shift reflects a broader movement within the healthcare landscape towards more targeted and sustainable therapeutic options, positioning RNA-based therapies as a pivotal force in the market's evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Amyloidosis Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Stem Cell Transplantation
• Targeted Therapy
• Supportive Care & Surgery
• Others

Global Amyloidosis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Amyloidosis Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• AL Amyloidosis
• ATTR Amyloidosis
• AA Amyloidosis
• Wild-Type ATTR

Global Amyloidosis Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Global Amyloidosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online

Global Amyloidosis Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attralus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zentalis Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations